Document:

Exhibit
10.22

 

SOURCING AND MARKETING AGREEMENT

 

This SOURCING AND
MARKETING AGREEMENT (“Agreement”) is made this 5th day of March, 2014 and shall be effective as of December
1, 2013 (“Effective Date”), by and between P.I.M.D. International, LLC (“PIMD”) and ScripsAmerica,
Inc. (“SCRIPS”). Each may be individually referred to as “Party” or jointly as the “Parties.”

 

In consideration of
the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the Parties, intending to be legally bound, agree to the following:

 

		1.	This Agreement is intended to establish a non-exclusive sourcing and marketing relationship between
SCRIPS and PIMD upon the terms and conditions provided herein, and shall be so interpreted.

 

		2.	Sourcing Services.

 

(a) SCRIPS is engaged in
the purchase, repackaging, labeling and nationwide distribution of various pharmaceutical products. As a result, SCRIPS has access
to pharmaceutical products for which a minimum order quantity is required, or for which a volume-based price discount is available,
or for which favorable payment terms are available, or for which certain financial capability is required. PIMD desires to obtain
the benefit of all such by contracting for SCRIPS’ sourcing services.

 

(b) SCRIPS may introduce
PIMD to various sources of both pharmaceutical products and financial support with which PIMD, in its sole discretion, may contract;
notwithstanding the separate and independent arrangements which PIMD may establish, the services of such third parties shall be
deemed services of SCRIPS hereunder for the purpose of measuring performance by SCRIPS of its sourcing duties and obligations hereunder.

 

(c)The foregoing shall be
subject to the prohibitions and limitations contained in sub-paragraphs 7(a) and 8(c).

 

		3.	Marketing Services.

 

(a) SCRIPS is a publicly-traded
company with growing name recognition and with nationwide distribution and marketing contacts. As a result, SCRIPS has entry and
access to market participants and segments which PIMD, as a start-up company, does not have. PIMD desires to obtain the benefit
of all such by contracting for SCRIPS’ marketing services.

 

(b) SCRIPS may introduce
PIMD to various distributors, sub-distributors, wholesalers, retailers, sales representatives, sales rep services, etc. with which
PIMD, in its sole discretion, may contract; notwithstanding the separate and independent arrangements which PIMD may establish,
the services of such third parties shall be deemed services of SCRIPS hereunder for the purpose of measuring performance by SCRIPS
of its marketing duties and obligations hereunder.

 

    	Page 1
                                                                                                                                                                                               of 9

    	 

    

 

(c) The foregoing shall be
subject to the prohibitions and limitations contained in sub-paragraphs 7(a) and 8(c).

 

		4.	Non-Exclusive Mutual Relationship.

 

(a)PIMD
acknowledges that SCRIPS has established networks of suppliers and distributors, that SCRIPS is engaged in similar or identical
business relationships and activities with other parties, and that PIMD’s relationship with SCRIPS is not exclusive, and
that SCRIPS is free to engage in similar or identical business relationships with other parties.

 

(b)SCRIPS acknowledges that
PIMD is a start-up company, that PIMD desires to establish favorable relationships with as many sources and marketers as possible,
and that PIMD is free to engage in similar or identical relationships with other parties.

 

		5.	Term. The initial Term of this Agreement shall commence as of December 1, 2013 and shall
continue until December 31, 2018 unless earlier terminated as set forth below. This Agreement shall automatically renew, for successive
five year terms, until and unless properly terminated as provided below.

 

		6.	Sourcing and Marketing Fee; Expenses.

 

(a)In consideration for SCRIPS
providing its services hereunder, PIMD shall pay to SCRIPS a Sourcing and Marketing Fee in an amount calculated as forty-five percent
(45%) of the Calculation Basis as defined herein (“Fee”). The Fee shall be calculated monthly based upon the data from
the preceding calendar month. The “Calculation Basis” is PIMD’s total receipts from paid invoices during the
preceding calendar month (i.e., total revenue on a cash basis) less the Allowable Deductions as defined herein. The “Allowable
Deductions” shall consist of (i) the purchase cost of the pharmaceutical products sold during the preceding calendar month,
together with the related in-bound freight and out-bound delivery costs, and the warehousing and storage costs allocated for such
sold products, (ii) rent, CDR salary per employment agreement, salesmen’s commissions and other reasonable overhead such
as telephone, utilities, office supplies, travel and entertainment, etc., but shall exclude (iii) interest, (iv) income taxes,
and (v) depreciation/amortization and other non-cash deductions. The Fee calculated for each month’s Calculation Basis shall
be paid to SCRIPS on or before the fifteenth calendar day of the succeeding month.  If such day is a holiday, payment shall
be made on the immediately prior business day.  Each Fee payment shall be accompanied by a report, in a form acceptable to
SCRIPS, detailing the calculation of the Fee payment for such preceding month.  There shall be no carryback nor carryforward
from month to month and no loss shall be distributed to SCRIPS. During the term of this Agreement, SCRIPS and its representatives
shall have continuing access to the books and records of PIMD in order to verify the data provided, and in the event of an error
or discrepancy, the Parties shall true-up the data and adjust currently for the underpayment or overpayment. Any true-up shall
be only with respect to correction of any data relied upon at the time of the calculation and payment of the Fee for any month.

 

    	Page 2
                                                                                                                                                                                               of 9

    	 

    

 

(b)SCRIPS shall be responsible
for payment of all of its normal costs and expenses incurred in the rendering of its sourcing and marketing services. However,
in connection with the rendering of all special services, as requested by PIMD, PIMD shall reimburse SCRIPS for out-of-pocket expenses
incurred upon presentation by SCRIPS of an itemized account of such expenditures, together with receipts or other proofs of the
expenditures.

 

7.
Obligations of PIMD. 

 

(a)PIMD, in conformity with
its due diligence requirements under state and federal law, may accept or reject any potential transaction or receipt or transfer
of any pharmaceutical products it deems, through its certified designated representative (CDR), to be non-conforming or potentially
non-conforming within the framework or interpretation of statutes or regulations related to wholesale pharmaceutical sales- and
transfer transactions, including, but not limited to receipt, storage, transfer, best manufacturing practices and pedigree requirements.
SCRIPS has no authority, right or power to require or bind PIMD to engage in any transaction related to the purchase, sale or transfer
of pharmaceutical products.

 

(b)PIMD hereby agrees that,
during the Term of this Agreement and any extensions or renewals thereof, it will:

 

		i.	Maintain current and in good standing all of the licenses and registrations required by law for
the wholesale distribution of pharmaceuticals and the conduct of its business under this Agreement.

 

		ii.	Administer all customer accounts in a commercially reasonable manner.

 

		iii.	Administer all customer accounts in accordance with all applicable federal, state, and local law
and in conformity with all ethical standards.

 

		iv.	Maintain facilities, equipment, and personnel sufficient to administer the customer accounts in
a professional and timely manner and in accordance with all applicable regulatory requirements.

 

		v.	Pay the Fee to SCRIPS in full and timely in accordance with the provisions set forth in Paragraph
6(a).

 

		vi.	Provide SCRIPS with (i) detailed accounting reports no less than monthly, showing all relevant
data in relation to the calculation of the Fee and (ii) access to the raw data used to prepare such reports. Provide SCRIPS with
audited financial statements annually.

 

		vii.	Provide SCRIPS with pricing, pricing lists or formulas as well as purchase and transfer procedures
to enable SCRIPS to make informed presentations or proposed offers to potential customer accounts.

 

    	Page 3
                                                                                                                                                                                               of 9

    	 

    

 

8.Obligations
of SCRIPS. SCRIPS hereby agrees that, during the Term of this Agreement and any renewals or extensions thereof, it will:

 

(a)Use its efforts to distribute
information relating to the pharmaceutical products provided by PIMD. Such information may include, but will not be limited to,
informational mailings, introductions, distribution of sales materials, organized efforts for communications with prospective clients,
participation in trade shows and conferences, and additional forms of information as agreed by the Parties.

 

(b)Obtain prior consent of
PIMD regarding all marketing communications to prospective customer accounts or suppliers concerning pharmaceutical products available
for purchase from, or sale by, PIMD.

 

(c)In providing its services
to PIMD, SCRIPS shall not engage in activities as a broker, obtain or make any payment for the purchase or sale of pharmaceutical
products, arrange for the transfer of any pharmaceutical product, receive or store any pharmaceutical product or make any binding
representation or warranty with regard to the purchase or sale of any pharmaceutical product. SCRIPS shall refer to PIMD, for its
resolution, all responsibility for the purchase or sale of any pharmaceutical products, the arrangements for the receipt and transfer
of any pharmaceutical products and any representation or warranties with regard to the purchase of any pharmaceutical products.

 

9.Warranties
and Representations of PIMD. PIMD makes the following warranties and representations, as an inducement to SCRIPS to
enter into this Agreement and with the intent that SCRIPS will rely on same:

 

(a)PIMD is a duly organized
limited liability company under the laws of the state of Florida and remains in good standing with all applicable licensing, regulatory
and governing authorities for the conduct of its business operations. At all times during the Term of this Agreement, PIMD shall
maintain all licenses and registrations for its business current and in good standing.

 

(b)PIMD is financially sound
and has the financial resources to perform this Agreement and to make all reasonably foreseeable expansions in its staff, facilities
and equipment necessary to perform hereunder in the future.

 

(c)PIMD is not engaged in
nor under investigation for any criminal activity, fraudulent activity or other activity reasonably construed as a deceptive or
unfair trade practice.

 

		10.	Warranties and Representations of SCRIPS. SCRIPS makes the following warranties and representations,
as an inducement to PIMD to enter into this Agreement and with the intent that PIMD will rely on same:

 

(a)SCRIPS is a duly organized
corporation under the laws of the state of Delaware and remains in good standing with all applicable licensing, regulatory and
governing authorities for the conduct of its business operations.

 

    	Page 4
                                                                                                                                                                                               of 9

    	 

    

 

(b) SCRIPS is financially
sound and has the financial resources to perform this Agreement and to make all reasonably foreseeable expansions in its staff,
facilities and equipment necessary to perform hereunder in the future.

 

(c) SCRIPS is not engaged
in nor under investigation for any criminal activity, fraudulent activity or other activity reasonably construed as a deceptive
or unfair trade practice.

 

		11.	Relationship of Parties.

 

(a) Independent Contractor
Relationship. The Parties intend that this Agreement shall not create or establish any partnership, joint venture, parent-subsidiary,
brother-sister, or other business entity or association between the Parties and, except as specifically provided herein, no Party
is intended to have any interest in the business, revenues, income, profits and losses, or property of the other by reason of this
Agreement.

 

(b) No Authority.
The Parties agree that neither of them shall have the authority to bind the other in contract nor to sign any document on behalf
of the other, and that neither of them shall indicate or imply such condition to any other person. SCRIPS has no authority, right
or power to require or bind PIMD to engage in any transaction related to the purchase, sale or transfer of pharmaceutical products.

 

12.Indemnification.

 

(a)PIMD hereby agrees to
indemnify, defend, and hold harmless, SCRIPS and its affiliates, and their respective directors, officers, employees, agents, and
representatives from any and all manner of third party claims and liabilities caused by or resulting from, in whole or in part,
the actions or omissions of PIMD, its staff or representatives, arising out of or related to the subject matter of this Agreement.

 

(b)SCRIPS hereby agrees to
indemnify, defend, and hold harmless, PIMD and its affiliates, and their respective members, directors, officers, employees, agents,
and representatives from any and all manner of third party claims and liabilities caused by or resulting from, in whole or in part,
the actions or omissions of SCRIPS, its staff or representatives, arising out of or related to the subject matter of this Agreement.

 

13. Survival.
Paragraph 12 and the Fee payment provisions of Paragraph 14 of this Agreement shall survive the termination of this Agreement,
and any renewal terms or other extensions thereof.

 

14.Termination.This
Agreement may only be terminated as follows:

 

(a)Mutual Agreement.
By mutual written agreement of the Parties at any time during the Term.

 

(b)Termination on Breach.
In the event that either Party materially breaches this Agreement at any time, this Agreement may be terminated by the non-breaching
Party as set forth below. A material breach includes, but is not limited to, any regulatory or statutory violation related to the
purchase or sale of pharmaceutical products, a Party’s breach of any of its representations or warranties contained in this
Agreement, PIMD’s failure to pay the Fee in accordance with the terms herein.

 

    	Page 5
                                                                                                                                                                                               of 9

    	 

    

 

i.If breach is by SCRIPS, PIMD
shall provide written notice to SCRIPS specifying the actions that constitute such material breach. If SCRIPS fails to cure such
breach within 30 calendar days of receipt of the PIMD notice, PIMD may terminate this Agreement immediately. In the event of such
termination by PIMD, it may seek to maintain its relationship with any current SCRIPS Accounts and SCRIPS shall not seek to interfere
with such relationships. Notwithstanding such termination, Scrips shall be entitled to the Fee calculated on customer accounts
in effect on the date of termination for the remainder of the Term of the Agreement as though the Agreement had not been terminated.

 

ii.If breach is by PIMD, SCRIPS
shall provide written notice to PIMD specifying the actions that constitute such material breach. If SCRIPS fails to cure (x) a
breach for failure to pay the Fee timely and in full within five business days, or (y) a breach for any other reason within 30
calendar days, of receipt of the SCRIPS notice, SCRIPS may terminate this Agreement immediately. In the event of such termination
by SCRIPS, it shall be entitled to payment of the Fee for a period of five years following the effective date of termination of
this Agreement. The obligations of PIMD set forth in Paragraphs 6 and 7 of this Agreement shall survive during the period in which
the Fee is required to be paid to SCRIPS under this provision. In addition to, and not in lieu of, its right to continuing payment
of the Fee, SCRIPS shall be entitled to encourage any of the customers that it referred to PIMD to cease doing business with PIMD
and encourage such customers or suppliers to engage in business with any other pharmaceutical wholesaler or supplier without liability
for any claim by PIMD for tortious interference, breach of contract or any other claim or remedy related to such conduct.

 

(c)Termination Due to
Agreement Revision.SCRIPS may terminate this Agreement as provided in Paragraph 15(a). In the event of such termination,
SCRIPS shall be entitled to the Fee calculated on customer accounts in effect on the date of termination for the remainder of the
Term of the Agreement as though the Agreement had not been terminated.

 

15. Miscellaneous.

 

(a)Severability. If
a court of competent jurisdiction holds any provision of this Agreement unenforceable or invalid, it is the intent of the Parties
that the court should modify the provision to give it the maximum legal effect in consideration of the original intent of the Parties
and that the various provisions contained herein shall remain in full force and effect as severable and independent clauses, however,
a modification of the calculation or payment of the Fee which is unacceptable to SCRIPS shall, in the discretion of SCRIPS, effect
a termination of this Agreement.

 

    	Page 6
                                                                                                                                                                                               of 9

    	 

    

 

(b) Notices. Any notice
or other communication required or permitted to be given under this Agreement shall be deemed to have been effectively given and
made if in writing and served by personal delivery to the Party for which it is intended, or by being sent via a commercially reasonable
carrier, to the following addresses:

 

	 	If to PIMD:	P.I.M.D. International,
LLC
	 	 	8280 NW 27th Street, Suite 506
	 	 	Doral, FL 33122
	 	 	Attn: Vanessa Gonzalez
	 	 	 
	 	With a copy to:	Bernard M. Cassidy, Esq.
			Lubell Rosen

			200 South Andrews Ave.

			Fort Lauderdale, FL 33301
	 	 	 
	 	If to SCRIPS:	ScripsAmerica,
Inc.
	 	 	843 Persimmon Lane
	 	 	Langhorne,
PA 19047
	 	 	Attn:Robert Schneiderman,
CEO
	 	 	 
	 	With a copy to:	Richard Fox,
Esq.
	 	 	561 NE Zebrina
Senda
	 	 	Jensen Beach, FL 34957

 

or to such other location as
a Party may designate in writing from time to time. For personal delivery, such notice shall be deemed delivered on the day of
receipt. A commercial carrier delivery shall be deemed delivered on the date shown on the receipt as delivered or first refused.
Notice sent to the attorneys for the Parties is a courtesy copy only and will not constitute notice to that Party.

 

(c)Construction. Whenever
used herein, the singular number shall include the plural, and the plural number shall include the singular, and use of any gender
or the neuter shall include all genders and the neuter. The paragraph headings in this Agreement are for convenience of reference
only and shall not be used as an aid in the construction of any provision. The Parties hereby agree that this Agreement is jointly
authored or hereby deemed prepared by each of the Parties, who further hereby agree to waive any rule of construction that may
apply for or against any Party due to its authorship.

 

(d)Choice of Law; Jurisdiction
and Venue; Enforcement Costs. This Agreement shall be governed by and construed in accordance with the laws of the State of
Florida. Venue and jurisdiction for any action related to or arising out of this Agreement shall be only in the state or federal
courts of the State of Florida. The prevailing Party in any action at law or in equity arising out of or related to this Agreement
shall be entitled to recover from the non-prevailing Party its costs at all levels, including without limitation its attorneys’
and accountants’ fees.

 

(e)Assignment and Delegation.
No Party may assign this Agreement, in whole or in part, without the prior written consent of the other Party. Any such non-consensual
assignment, sublicense, subcontract or encumbrance of this Agreement shall be invalid and of no force or effect.

 

    	Page 7
                                                                                                                                                                                               of 9

    	 

    

 

(f)Wavier and Modification.
No failure on the part of any Party to exercise any right under this Agreement shall operate as a waiver of such right; nor shall
any single or partial exercise of any right preclude any other or further exercise or the exercise of any other rights. This Agreement
may only be modified in a writing signed by both Parties.

 

(g)Third Party Beneficiaries.
The Parties specifically agree that this Agreement is not intended by any of its provisions to create a third party beneficiary
interest in the public or any member thereof or to authorize anyone not a party to this contract to maintain a suit for injuries
or property damages by reason of its contents.

 

(h)Successors. The
provisions of this Agreement shall inure to the benefit of and shall be binding on the permitted assigns and successors in interest
of each of the Parties.

 

(i)Entire Agreement.
This Agreement contains the entire understanding between the Parties concerning the subject matter contained herein. The Parties
hereby acknowledge and agree that there are no representations, agreements, arrangements, or understandings, oral or written, between
or among the Parties relating to the subject matter of this Agreement that are not fully expressed herein and that no Party has
relied on the statement of any other as an inducement to enter into this Agreement.

 

(j)Counterparts and Signatures.
This Agreement may be executed in one or more counterparts and, in making proof of this Agreement, it shall not be necessary to
produce or account for more than one fully executed counterpart hereof. A faxed or electronic signature shall have the same effect
as an original.

 

[signature page follows]

 

 

 

 

    	Page 8
                                                                                                                                                                                               of 9

    	 

    

 

IN WITNESS WHEREOF,
the duly authorized officers of the Parties have executed this Agreement, intending to be legally bound, as of the date first written
above.

 

 

P.I.M.D. International, LLC

 

 

By: /s/Vanessa Gonzalez

Vanessa Gonzalez,
as Manager and Sole Member

 

 

 

ScripsAmerica, Inc.

 

 

By: /s/Robert Schneiderman

Robert Schneiderman, CEO

 

    	Page 9 of 9EXHIBIT 10.23

 

PROMISSORY NOTE

 

	$262,000.00	October 1, 2013

 

	BORROWER:	Implex Corporation 
	 	4650 Wedekind Road, Suite 2
	 	Sparks, NV 89431-7722

 

(Hereinafter referred to as “Borrower”)

 

	LENDER:	ScripsAmerica, Inc.
	 	843 Persimmon Lane
	 	Langhorne, PA 19047

 

(Hereinafter referred to as “Lender”)

 

Borrower promises to pay to the order of
Lender, in lawful money of the United States of America, by wiring to the financial institution account specified hereinafter or
wherever else Lender may specify, the sum of Two Hundred Sixty-two Thousand Dollars ($262,000.00) or such sum as may be advanced
and outstanding from time to time, with base interest and participating interest on the unpaid principal balance at the rate and
on the terms provided in this Promissory Note (including all renewals, extensions or modifications hereof, this “Note”).

 

DEFINITIONS.

 

	a.		The term “Obligations”, as used in this Note, refers to any and
all indebtedness and other obligations under this Note.

 

	b.		All terms that are used but not otherwise defined shall have the definitions provided
in the Uniform Commercial Code in effect in the State of Nevada.

 

SECURITY/GUARANTY. Lender has waived
(a) any lien encumbrance or security interest in the property and assets of the Borrower and (b) any personal guaranty by the shareholders
of the Borrower.

 

BASE INTEREST RATE. Interest shall
accrue on the unpaid principal balance of this Note outstanding from time to time from the date hereof at two percent (2%) per
annum (the “Base Interest Rate”). Interest shall be due and payable on or before the fifteenth day of the month
following the end of each calendar quarter.

 

DEFAULT RATE. In addition to all
other rights contained in this Note, if a Default (as defined herein) occurs and as long as a Default continues, all outstanding
Obligations shall bear interest at the Default Interest Rate of six percent (6%) per annum simple interest (the “Default
Rate”) instead of the Base Interest Rate of two percent (2%). The Default Rate shall also apply from acceleration until
the Obligations or any judgment thereon is paid in full.

 

    	1

    	 

    

 

INTEREST AND FEE(S) COMPUTATION (ACTUAL/360).
Interest and fees, if any, shall be computed on the basis of a 360-day year for the actual number of days in the applicable period
(“Actual/360 Computation”). The Actual/360 Computation determines the annual effective interest yield by taking
the stated (nominal) rate for a year's period and then dividing said rate by 360 to determine the daily periodic rate to be applied
for each day in the applicable period. Application of the Actual/360 Computation produces an annualized effective rate exceeding
the nominal rate.

 

REPAYMENT TERMS. This Note shall
have a term of five (5) years and five (5) months with a maturity date of February 28, 2019 (“Maturity Date”), without
amortization. The outstanding principal balance of this Note, together with all accrued and unpaid interest thereon, and any and
all other sums due hereunder, shall mature and be due and payable to Lender on the Maturity Date.

 

APPLICATION OF PAYMENTS. Monies
received by Lender from any source for application toward payment of the Obligations shall be applied to accrued interest and then
to principal. If a Default (as defined below) occurs, monies may be applied to the Obligations in any manner or order deemed appropriate
by Lender. If any payment received by Lender under this Note or other Loan Documents is rescinded, voided or for any reason returned
by Lender because of any adverse claim or threatened action, the returned payment shall remain payable as an obligation of all
persons liable under this Note or other Loan Documents as though such payment had not been made.

 

LATE CHARGE. If any payments are
not timely made, Borrower shall also pay to Lender a late charge equal to five percent (5%) of each payment past due for five (5)
or more days. Acceptance by Lender of any late payment without an accompanying late charge shall not be deemed a waiver of Lender's
right to collect such late charge or to collect a late charge for any subsequent late payment received.

 

ATTORNEYS’ FEES AND OTHER COLLECTION
COSTS. Borrower shall pay all of Lender’s reasonable expenses actually incurred to enforce or collect any of the Obligations
including, without limitation, reasonable arbitration, paralegals’, attorneys’ and experts’ fees and expenses,
whether incurred without the commencement of a suit, in any trial, arbitration, or administrative proceeding, or in any appellate
or bankruptcy proceeding.

DEFAULT. If any of the following
occurs, a default under this Note (a “Default”) shall exist:

 

	a.		Nonpayment; Nonperformance. The failure to make any payment, or perform any
obligation, under this Note within ten (10) business days of the due date, which failure is not cured within ten (10) days of
the date that written notice of such failure is given by Lender to Borrower.

 

    	2

    	 

    

 

	b.		Cessation; Bankruptcy. The dissolution of, termination of existence of, loss
of good standing status by, appointment of a receiver for, assignment for the benefit of creditors of, or commencement of any
bankruptcy or insolvency proceeding by or against Borrower.

 

REMEDIES UPON DEFAULT. If a Default
occurs under this Note, Lender may, at any time thereafter, take any of the following actions: (a) accelerate the maturity of this
Note and, at Lender’s option, any or all other Obligations, whereupon this Note and the accelerated Obligations shall be
immediately due and payable; provided, however, if the Default is based upon a bankruptcy or insolvency proceeding commenced by
or against Borrower or any guarantor or endorser of this Note, all Obligations shall automatically and immediately be due and payable;
and/or (b) exercise any rights and remedies as provided under the Note or as provided by law or equity. The remedies of the Lender
set forth above shall be cumulative.

 

WAIVERS AND AMENDMENTS. No waivers,
amendments or modifications of this Note shall be valid unless in writing and signed by an officer of Lender. No waiver by Lender
of any Default shall operate as a waiver of any other Default or the same Default on a future occasion. Neither the failure nor
any delay on the part of Lender in exercising any right, power, or remedy under this Note shall operate as a waiver thereof, nor
shall a single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power
or remedy.

 

Except to the extent prohibited by law,
Borrower and each other person liable under this Note waives presentment, protest, notice of dishonor, demand for payment, notice
of intention to accelerate maturity, notice of acceleration of maturity, notice of sale and all other notices of any kind. Further,
each agrees that Lender may (i) extend, modify or renew this Note or make a novation of the loan evidenced by this Note,
and/or (ii) grant releases, compromises or indulgences with respect to any collateral securing this Note, or with respect to Borrower
or any other person liable under this Note, all without notice to or consent of Borrower and other such person, and without affecting
the liability of Borrower and other such person; provided, Lender may not extend, modify or renew this Note or make a novation
of the loan evidenced by this Note without the consent of the Borrower, or if there is more than one Borrower, without the consent
of at least one Borrower; and further provided, if there is more than one Borrower, Lender may not enter into a modification of
this Note which increases the burdens of a Borrower without the consent of that Borrower.

 

MISCELLANEOUS PROVISIONS. 

 

Assignment. This Note shall inure
to the benefit of and be binding upon the parties and their respective heirs, legal representatives, successors and assigns. Lender's
interests in and rights under this Note are freely assignable, in whole or in part, by Lender. In addition, nothing in this
Note shall prohibit Lender from pledging or assigning this Note or any interest therein. Borrower shall not assign its rights and
interest hereunder without the prior written consent of Lender, and any attempt by Borrower to assign without Lender's prior written
consent is null and void. Any assignment shall not release Borrower from the Obligations.

 

    	3

    	 

    

 

Applicable Law. This Note shall
be governed by and interpreted in accordance with federal law and, except as preempted by federal law, the laws of the State of
Nevada without regard to that state's conflict of laws principles.

 

Severability. If any provision of
this Note shall be prohibited or invalid under applicable law, such provision shall be ineffective but only to the extent of such
prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Note or other
such document.

 

Advances. Lender may, with the agreement
of Borrower, make other advances which shall be deemed to be advances under this Note, even though the stated principal amount
of this Note may be exceeded as a result thereof.

 

Fees and Taxes. Borrower shall promptly
pay all documentary, intangible recordation and/or similar taxes on this transaction whether assessed at closing or arising from
time to time.

 

Final Agreement. This Note represent
the final agreement between the parties and may not be contradicted by evidence of prior, contemporaneous or subsequent agreements
of the parties. There are no unwritten agreements between the parties.

 

WAIVER OF JURY TRIAL. TO THE EXTENT
PERMITTED BY APPLICABLE LAW, BORROWER BY EXECUTION HEREOF, KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVES ANY RIGHT IT MAY HAVE
TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION BASED ON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE OR ANY AGREEMENT
CONTEMPLATED TO BE EXECUTED IN CONNECTION WITH THIS NOTE, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER VERBAL
OR WRITTEN) OR ACTIONS OF ANY PARTY WITH RESPECT HERETO. THIS PROVISION IS A MATERIAL INDUCEMENT TO LENDER TO ACCEPT THIS NOTE.
BORROWER AGREES THAT THE TERMS HEREOF SHALL SUPERSEDE AND REPLACE ANY PRIOR AGREEMENT RELATED TO ARBITRATION OF DISPUTES BETWEEN
THE PARTIES CONTAINED IN ANY LOAN DOCUMENT OR ANY OTHER DOCUMENT OR AGREEMENT HERETOFORE EXECUTED IN CONNECTION WITH, RELATED TO
OR BEING REPLACED, SUPPLEMENTED, EXTENDED OR MODIFIED BY, THIS NOTE.

 

    	4

    	 

    

 

IN WITNESS WHEREOF, Borrower, on the day and year first
above written, has caused this Promissory Note to be duly executed under seal.

 

 

BORROWER:

 

Implex Corporation, a Nevada corporation

 

 

By: /s/ Richard C. Fox

Name: Richard C. Fox, President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]